Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • بيانات النشر:
      BMC, 2018.
    • الموضوع:
      2018
    • Collection:
      LCC:Infectious and parasitic diseases
    • نبذة مختصرة :
      Abstract Background Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a once-daily integrase inhibitor-based regimen. Methods We analyzed data from SCOLTA prospective database. All patients with HIV-RNA
    • File Description:
      electronic resource
    • ISSN:
      1471-2334
    • Relation:
      http://link.springer.com/article/10.1186/s12879-018-3268-5; https://doaj.org/toc/1471-2334
    • الرقم المعرف:
      10.1186/s12879-018-3268-5
    • الرقم المعرف:
      edsdoj.8b86a5ad270f4835936a6a9ce8fc3e78